Powering Global Biotech Growth

How unified development and manufacturing ecosystems can accelerate innovation, strengthen cross-border collaboration and bring assets to market faster

 

China’s biopharma industry is rapidly emerging as a global innovation powerhouse. Record-breaking licensing-out activity, a maturing innovation ecosystem and growing cross-border collaboration are reshaping the global biopharmaceutical landscape.

 

For biotech and pharmaceutical companies worldwide, this evolution is creating significant new opportunities. Innovative assets are reaching global partners earlier, development models are becoming more integrated, and organisations are looking for ways to shorten timelines while maintaining quality, resilience and regulatory confidence. At the same time, successful cross-border collaboration requires trusted partnerships capable of supporting programmes from development through commercialisation.

 

As a result, executive leaders are re-evaluating how development and manufacturing strategies are structured - exploring unified ecosystems that connect scientific expertise, integrated CMC capabilities and global delivery in order to accelerate progress and capture the next generation of biotech opportunities.

Join us to network with your peers and gain practical insights into China’s evolving biopharma ecosystem, emerging licensing trends and the role of strategic partnerships in accelerating drug development. This is an exclusive event and seat numbers are very limited, so apply for your place now.

 

The questions we will explore

 

During the meeting, we will focus on topics such as:

 

• How is the maturation of Asia’s innovation ecosystem reshaping the global biopharma landscape?

• What is driving the rapid growth of licensing-out activity, and how should global companies respond?

• How can integrated CMC capabilities help break down development timelines and accelerate asset commercialisation?

• What operating models can connect development and manufacturing more effectively across the biopharma value chain?

• How can organisations build trusted cross-border partnerships while managing quality, regulatory and delivery risk?

• Where are the most significant next-generation biotech opportunities likely to emerge?

 

Who is invited?

 

This discussion over dinner is designed for executive leaders and senior decision-makers across biotech, pharmaceutical and investment organisations, including Chief Executive Officers, Chief Financial Officers, General Managers, Chief Scientific Officers, Department Heads, Directors and other senior leaders reporting directly to the executive team.

 

Be one of 12 senior professionals attending this event at the House of Lords in London. For any enquiries, please contact Mergim Begolli on 020 8349 6458 or email m.begolli@business-reporter.co.uk.

 

Sponsored dinner is brought to you by Asymchem and is only for senior executives, as mentioned above. Registrations of consultants, solution providers or other sellers to this market won’t be accepted. To be eligible, you must hold an executive or senior leadership role within a biotech, pharmaceutical, life sciences or investment organisation.

 

This event is free of charge to attend.

 

When you register, we will ask you for your corporate email address, which we will share only with the event sponsor(s). See our privacy policy